FI3989961T3 - Artemisiniiniyhdisteen, 5-aminolevuliinihapon tai metyyli-5-aminolevuliinihapon ja kemoterapeuttisen aineen farmaseuttinen yhdistelmä - Google Patents
Artemisiniiniyhdisteen, 5-aminolevuliinihapon tai metyyli-5-aminolevuliinihapon ja kemoterapeuttisen aineen farmaseuttinen yhdistelmä Download PDFInfo
- Publication number
- FI3989961T3 FI3989961T3 FIEP21705541.7T FI21705541T FI3989961T3 FI 3989961 T3 FI3989961 T3 FI 3989961T3 FI 21705541 T FI21705541 T FI 21705541T FI 3989961 T3 FI3989961 T3 FI 3989961T3
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical composition
- aminolevulinic acid
- cancer
- use according
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20158341.6A EP3868372A1 (en) | 2020-02-19 | 2020-02-19 | A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer |
| PCT/EP2021/054039 WO2021165405A1 (en) | 2020-02-19 | 2021-02-18 | A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3989961T3 true FI3989961T3 (fi) | 2024-02-14 |
Family
ID=69779738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21705541.7T FI3989961T3 (fi) | 2020-02-19 | 2021-02-18 | Artemisiniiniyhdisteen, 5-aminolevuliinihapon tai metyyli-5-aminolevuliinihapon ja kemoterapeuttisen aineen farmaseuttinen yhdistelmä |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230121771A1 (https=) |
| EP (2) | EP3868372A1 (https=) |
| JP (1) | JP7719787B2 (https=) |
| KR (1) | KR20220143097A (https=) |
| CN (1) | CN114786661A (https=) |
| AU (1) | AU2021222339A1 (https=) |
| BR (1) | BR112022014692A2 (https=) |
| CA (1) | CA3165208A1 (https=) |
| DK (1) | DK3989961T3 (https=) |
| ES (1) | ES2972799T3 (https=) |
| FI (1) | FI3989961T3 (https=) |
| IL (1) | IL294856A (https=) |
| PL (1) | PL3989961T3 (https=) |
| PT (1) | PT3989961T (https=) |
| WO (1) | WO2021165405A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220184234A1 (en) * | 2020-11-30 | 2022-06-16 | Sonalasense, Inc. | Metabolic targeting of low grade tumors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU225148B1 (en) | 1995-03-10 | 2006-07-28 | Photocure Asa | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy or diagnosis, products and kits comprising thereof and method of in vitro diagnosis by their using |
| GB0018528D0 (en) | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| TWI482621B (zh) * | 2009-12-23 | 2015-05-01 | Sigma Tau Ind Farmaceuti | 青蒿素基藥物與其他化學治療劑的抗癌組合物 |
| JP2011225471A (ja) * | 2010-04-16 | 2011-11-10 | Univ Of Tsukuba | 抗癌剤の効果増強剤 |
| US10925963B2 (en) * | 2015-06-22 | 2021-02-23 | Washington University | Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor |
| CN105963244A (zh) * | 2016-01-15 | 2016-09-28 | 赵鸣 | 注射用青蒿琥酯制剂及其应用 |
| CN106527586B (zh) * | 2016-11-04 | 2019-09-06 | 吉林省北方医药有限责任公司 | 一种移动终端设备 |
| CN108570089B (zh) * | 2017-04-28 | 2019-10-29 | 云白药征武科技(上海)有限公司 | 双氢青蒿素-甾体结合物及其制备方法和应用 |
| GB201800736D0 (en) * | 2018-01-17 | 2018-02-28 | St Georges Hospital Medical School | Combination therapy for treatment of leukemia |
| CN108635581A (zh) * | 2018-05-23 | 2018-10-12 | 昆药集团股份有限公司 | 一种组合物及其在制备治疗肿瘤的药物中的应用 |
-
2020
- 2020-02-19 EP EP20158341.6A patent/EP3868372A1/en active Pending
-
2021
- 2021-02-18 ES ES21705541T patent/ES2972799T3/es active Active
- 2021-02-18 BR BR112022014692A patent/BR112022014692A2/pt unknown
- 2021-02-18 WO PCT/EP2021/054039 patent/WO2021165405A1/en not_active Ceased
- 2021-02-18 EP EP21705541.7A patent/EP3989961B1/en active Active
- 2021-02-18 DK DK21705541.7T patent/DK3989961T3/da active
- 2021-02-18 FI FIEP21705541.7T patent/FI3989961T3/fi active
- 2021-02-18 KR KR1020227032196A patent/KR20220143097A/ko active Pending
- 2021-02-18 AU AU2021222339A patent/AU2021222339A1/en active Pending
- 2021-02-18 US US17/801,021 patent/US20230121771A1/en active Pending
- 2021-02-18 PL PL21705541.7T patent/PL3989961T3/pl unknown
- 2021-02-18 JP JP2022550755A patent/JP7719787B2/ja active Active
- 2021-02-18 IL IL294856A patent/IL294856A/en unknown
- 2021-02-18 CA CA3165208A patent/CA3165208A1/en active Pending
- 2021-02-18 PT PT217055417T patent/PT3989961T/pt unknown
- 2021-02-18 CN CN202180007033.7A patent/CN114786661A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220143097A (ko) | 2022-10-24 |
| PL3989961T3 (pl) | 2024-04-08 |
| IL294856A (en) | 2022-09-01 |
| CA3165208A1 (en) | 2021-08-26 |
| CN114786661A (zh) | 2022-07-22 |
| JP2023514426A (ja) | 2023-04-05 |
| AU2021222339A1 (en) | 2022-07-28 |
| EP3989961A1 (en) | 2022-05-04 |
| ES2972799T3 (es) | 2024-06-17 |
| PT3989961T (pt) | 2024-02-26 |
| EP3868372A1 (en) | 2021-08-25 |
| WO2021165405A1 (en) | 2021-08-26 |
| EP3989961B1 (en) | 2023-11-22 |
| BR112022014692A2 (pt) | 2022-09-20 |
| US20230121771A1 (en) | 2023-04-20 |
| JP7719787B2 (ja) | 2025-08-06 |
| DK3989961T3 (da) | 2024-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512121A5 (https=) | ||
| US12083096B2 (en) | Composition containing artesunate | |
| KR20110132371A (ko) | Ｒｄｅａ１１９／ｂａｙ ８６９７６６을 포함하는 특정 암의 치료를 위한 제약 조합물 | |
| WO2012065079A4 (en) | Methods of treating cancer | |
| WO2014157444A1 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| US20190060317A1 (en) | Compositions and methods for treating cancer | |
| JP2021512110A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| Chuang et al. | Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy | |
| FI3989961T3 (fi) | Artemisiniiniyhdisteen, 5-aminolevuliinihapon tai metyyli-5-aminolevuliinihapon ja kemoterapeuttisen aineen farmaseuttinen yhdistelmä | |
| WO2018127575A1 (en) | Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof | |
| US20240245704A1 (en) | Pharmaceutical composition and use of multi-kinase inhibitor | |
| US11186594B2 (en) | Podophyllotoxin derivatives and their use | |
| US20190231793A1 (en) | Use of harringtonines in the treatment of breast cancer, in particular triple-negative breast cancer | |
| CN108524533A (zh) | 一种化合物用作抗肿瘤药物增效剂和逆转剂 | |
| CN101357134A (zh) | 抗肿瘤效果增强剂和抗肿瘤剂 | |
| US20050288378A1 (en) | Cancer chemotherapy | |
| WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
| RU2657604C2 (ru) | Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана | |
| CA3049095C (en) | Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof | |
| CA2569739C (en) | Antitumor effect potentiator, antitumor preparation, and method for treating cancer | |
| JP2023514426A5 (https=) | ||
| CN110693903B (zh) | 一种治疗急性单核细胞白血病的药物及三氧化二砷和双氢青蒿素的应用 | |
| CN115364109A (zh) | 一种用于肺癌治疗的药物制剂 | |
| CN114642666A (zh) | 含有帕博西尼和紫杉醇的药物组合物及应用 | |
| Tang et al. | Synthesis and pharmacological evaluation of natural product Diphyllin derivatives against head and neck squamous cell carcinoma |